The extravasation of leukocytes from the peripheral blood stream to inflammatory sites is a key feature in the innate immune response to infection (1). Different chemoattractants (e.g. N-formylated peptides, C5a, interleukin-8, leukotriene B 4 , and platelet-activating factor) and chemokines induce leukocyte infiltration and activation through binding to G proteincoupled seven-transmembrane cell-surface receptors (2, 3). The chemoattractant-mediated dissociation of G␣ i2 from the G␥ subunit complex results in the activation of several downstream signaling effector enzymes that promote intracellular calcium mobilization, modifications in the metabolism of phosphoinositides, and activation of mitogen-activated protein kinases (4). The integration by the cell of the different chemoattractant-activated signaling pathways results in directed cell migration, recruitment of new receptors from the granules to the cell surface, release of proteolytic enzymes, production of large amounts of superoxide by the neutrophil NADPH oxidase, and increased gene transcription (5-8). The extent of the cellular response is dependent on the identity of the agonist and on the level of expression and desensitization of the receptors involved in the activation process (9).Two synthetic hexapeptides, Trp-Lys-Tyr-Met-Val-Met-NH 2 (WKYMVM)andTrp-Lys-Tyr-Met-Val-D-Met-NH 2 (WKYMVm), that stimulate phosphoinositide hydrolysis in myeloid cells were identified by screening a peptide library (10, 11). The D-methionine-containing hexapeptide (WKYMVm) was found to be a very potent activator of several leukocyte effector functions such as chemotaxis, mobilization of complement receptor-3, and activation of the NADPH oxidase (11). The peptide WKYMVm activates neutrophils through both the N-formyl peptide receptor (FPR) 1 and FPRL1 (N-formyl peptide receptor-like-1) (12, 13). The latter was originally cloned from human phagocytes by low-stringency hybridization of a cDNA library with the FPR cDNA sequence, and it was initially defined as an orphan receptor (14 -16). FPRL1 was later referred to as the LXA 4 receptor since it was shown to bind lipoxin A 4 with high affinity (17). In addition, several different peptides/proteins have been reported to stimulate this receptor. These include a leucine zipper-like domain of the HIV-1